Related Experiment Video
Updated: Jul 16, 2026
08:39
Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
Published on: May 16, 2022
G protein beta3 polymorphism and triptan response in cluster headache.
1Department of Neurology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Clinical Pharmacology and Therapeutics
|March 16, 2007
Summary
A common genetic variant in the G protein beta3 subunit (GNB3 C825T) significantly influences cluster headache (CH) treatment response to triptans. This finding may personalize CH therapy by identifying patients likely to benefit from triptans.
Area of Science:
- Genetics
- Pharmacogenomics
- Neurology
Background:
- Triptans, agonists of 5-HT(1B/D) receptors, provide significant relief for only about 70% of migraine and cluster headache (CH) patients.
- G protein-coupled receptors, including the 5-HT(1B/D) receptor, play a crucial role in neurotransmission and drug response.
- The G protein beta3 subunit (GNB3) is involved in signal transduction pathways downstream of G protein-coupled receptors.
Purpose of the Study:
- To investigate whether a common polymorphism in the GNB3 gene (C825T) influences treatment response rates to triptans in Caucasian cluster headache (CH) patients.
- To determine if the GNB3 genotype modulates the efficacy of triptan therapy for CH.
Main Methods:
- A cohort of 231 unrelated Caucasian CH patients was genotyped for the GNB3 C825T polymorphism.
- Treatment response to triptans was assessed in 180 CH patients who used these medications.
- Statistical analysis, including calculation of adjusted odds ratios, was performed to evaluate the association between GNB3 genotype and triptan response.
Main Results:
- The overall treatment success rate for triptans in the studied CH cohort was 71.1%.
- Heterozygous carriers of the GNB3 825T allele showed a significantly higher odds ratio (2.96) for treatment response to triptans compared to carriers of the 825CC genotype (P=0.0074).
- The GNB3 genotype status did not impact the response to other therapeutic regimens, such as oxygen, verapamil, or corticosteroids, which do not directly affect G proteins.
Conclusions:
- A common genetic variant, GNB3 C825T, significantly modulates pain relief efficacy of triptans in cluster headache patients.
- This genetic marker may serve as a predictor for triptan responsiveness in CH, potentially guiding personalized treatment strategies.
- The findings highlight the role of G protein signaling in triptan action and suggest a pharmacogenetic basis for variable treatment outcomes.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:22Activation and Inactivation of G Proteins
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high affinity and are together...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:12GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...